Zoetis (ZTS) Set to Announce Earnings on Thursday

Zoetis (NYSE:ZTS) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, May 2nd. Analysts expect Zoetis to post earnings of $1.35 per share for the quarter. Zoetis has set its FY24 guidance at $5.74 to $5.84 EPS and its FY 2024 guidance at 5.740-5.840 EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The business had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The business’s revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.15 earnings per share. On average, analysts expect Zoetis to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Zoetis Stock Performance

Shares of ZTS opened at $150.89 on Thursday. The firm has a market cap of $69.01 billion, a PE ratio of 29.76, a PEG ratio of 2.22 and a beta of 0.85. The stock’s fifty day moving average price is $173.11 and its two-hundred day moving average price is $179.58. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. Zoetis has a 1 year low of $144.80 and a 1 year high of $201.92.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be paid a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.15%. Zoetis’s payout ratio is 34.12%.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $197.74, for a total transaction of $71,779.62. Following the completion of the transaction, the executive vice president now owns 20,417 shares of the company’s stock, valued at approximately $4,037,257.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 2,209 shares of company stock worth $371,293 in the last ninety days. 0.15% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms recently commented on ZTS. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. The Goldman Sachs Group upped their price objective on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Stifel Nicolaus cut their price objective on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd. Piper Sandler reiterated an “overweight” rating and issued a $195.00 price objective (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Finally, Barclays cut their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $218.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.